ArticleOncology reports2024

The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence.

Huan Gui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.